Cargando…

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA

BACKGROUND: Randomized phase III trials have established the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation-positive advanced non–small-cell lung cancer (EGFR Mut+ NSCLC). This retrospective cohort study examined the managemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yulin, Appius, Anita, Pattipaka, Thirupathi, Feyereislova, Andrea, Cassidy, Adrian, Ganti, Apar Kishor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319739/ https://www.ncbi.nlm.nih.gov/pubmed/30608948 http://dx.doi.org/10.1371/journal.pone.0209709

Ejemplares similares

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Promising trends in lung cancer care, but are we overlooking the majority?
por: Sharma, Bhavina, et al.
Publicado: (2023)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

Current concepts in the management of small cell lung cancer
por: Ganti, Apar Kishor, et al.
Publicado: (2013)

Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
por: Bhatt, Vijaya Raj, et al.
Publicado: (2016)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
por: Liu, Jun-Feng, et al.
Publicado: (2023)

Pancytopenia due to iron deficiency worsened by iron infusion: a case report
por: Ganti, Apar Kishor, et al.
Publicado: (2007)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
por: Anggondowati, Trisari, et al.
Publicado: (2020)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios, Giannis, et al.
Publicado: (2021)

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

P796: HOSPITALIZATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A RETROSPECTIVE ANALYSIS OF OBSERVATIONAL STUDY DATA FROM THE UNITED STATES
por: Shammo, Jamile, et al.
Publicado: (2023)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
por: Xu, Ziyi, et al.
Publicado: (2022)

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
por: Cuppens, Kristof, et al.
Publicado: (2021)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
por: Park, Keunchil, et al.
Publicado: (2019)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma
por: Dhakal, Prajwal, et al.
Publicado: (2014)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
por: Averell, Carlyne M, et al.
Publicado: (2019)

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Characterizing Immune Checkpoint Inhibitor-Induced Hypophysitis and Obstacles in Diagnosis
por: Johnson, Jake, et al.
Publicado: (2021)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study
por: Mountzios, Giannis, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Predicting EGFR mutational status from pathology images using a real-world dataset
por: Pao, James J., et al.
Publicado: (2023)

Weight Loss and Percutaneous Endoscopic Gastrostomy Tube Placement during Chemoradiotherapy for Locally Advanced Cancer of the Oropharynx Do Not Negatively Impact Outcomes
por: Baine, Michael J., et al.
Publicado: (2017)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
por: Hu, Chunhong, et al.
Publicado: (2022)

Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014)

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
por: Lee, Jang Ho, et al.
Publicado: (2023)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
por: Urbanska, Edyta M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7spt64gs2u6l1hl631lb478ri9